Form 4: Neurocrine Biosciences Director Exercises Stock Options

Director Stephen A. Sherwin exercised stock options, acquiring 4,199 shares of Neurocrine Biosciences common stock on May 17, 2024.

Summary

• On May 17, 2024, Stephen A. Sherwin, a director of Neurocrine Biosciences Inc., exercised stock options.
• This transaction involved the acquisition of 4,199 shares of common stock at a price of $0 per share.
• Following the transaction, Sherwin directly owns 26,504 shares of Neurocrine Biosciences common stock.
• The exercised options were Restricted Stock Units (RSUs) that vested on May 17, 2023.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard disclosure of insider transactions. The exercise of options is neither inherently positive nor negative without further context.

Positives

• The exercise of vested stock options by a director can be seen as a positive signal, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. They are closely watched by investors for signals about management's view of the company's prospects.

Stakeholder Impact

• The transaction could have a minor impact on shareholders by slightly increasing the number of outstanding shares.

Key Dates